News

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript

  • Exagen Inc. (NASDAQ:XGN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Griffin Soriano - William Blair Ross Osborn - Cantor Fitzgerald Ryan Douglas Good afternoon, and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022.
    08/06/2022

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

  • SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
    07/21/2022
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Exagen Inc. (XGN) can buy. Click on Rating Page for detail.

The price of Exagen Inc. (XGN) is 4.98 and it was updated on 2022-08-17 01:53:57.

Currently Exagen Inc. (XGN) is in undervalued.

News
    
News

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2022 Results - Earnings Call Transcript

  • Exagen Inc. (NASDAQ:XGN ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Brian Weinstein - William Blair Kyle Mikson - Canaccord Operator Greetings, ladies and gentlemen, and welcome to the Exagen, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded.
    Wed, May. 11, 2022

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

  • Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
    Wed, May. 11, 2022

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

  • SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
    Mon, Apr. 25, 2022

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript

  • Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
    Tue, Mar. 22, 2022

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

  • Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
    Tue, Mar. 22, 2022
SEC Filings
SEC Filings

Exagen Inc. (XGN) - S-8

  • SEC Filings
  • 05/11/2022

Exagen Inc. (XGN) - DEFA14A

  • SEC Filings
  • 04/28/2022

Exagen Inc. (XGN) - DEF 14A

  • SEC Filings
  • 04/28/2022

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 02/15/2022

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/14/2022

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/11/2022

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/10/2022

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/08/2022

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 01/20/2022

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 01/19/2022

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 12/27/2021

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 12/17/2021

Exagen Inc. (XGN) - S-8

  • SEC Filings
  • 05/11/2021

Exagen Inc. (XGN) - DEFA14A

  • SEC Filings
  • 04/27/2021

Exagen Inc. (XGN) - DEF 14A

  • SEC Filings
  • 04/27/2021

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 04/09/2021

Exagen Inc. (XGN) - 424B5

  • SEC Filings
  • 03/23/2021

Exagen Inc. (XGN) - 424B5

  • SEC Filings
  • 03/22/2021

Exagen Inc. (XGN) - SC 13D

  • SEC Filings
  • 02/24/2021

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/16/2021

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/12/2021

Exagen Inc. (XGN) - SC 13G/A

  • SEC Filings
  • 02/11/2021

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 02/11/2021

Exagen Inc. (XGN) - EFFECT

  • SEC Filings
  • 11/19/2020

Exagen Inc. (XGN) - CORRESP

  • SEC Filings
  • 11/17/2020

Exagen Inc. (XGN) - UPLOAD

  • SEC Filings
  • 11/16/2020

Exagen Inc. (XGN) - S-3

  • SEC Filings
  • 11/10/2020

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 09/18/2020

Exagen Inc. (XGN) - DEFA14A

  • SEC Filings
  • 04/29/2020

Exagen Inc. (XGN) - DEF 14A

  • SEC Filings
  • 04/29/2020

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 02/14/2020

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 02/07/2020

Exagen Inc. (XGN) - SC 13G

  • SEC Filings
  • 01/27/2020

Exagen Inc. (XGN) - S-8

  • SEC Filings
  • 09/20/2019

Exagen Inc. (XGN) - 424B4

  • SEC Filings
  • 09/20/2019

Exagen Inc. (XGN) - S-1MEF

  • SEC Filings
  • 09/18/2019

Exagen Inc. (XGN) - EFFECT

  • SEC Filings
  • 09/18/2019

Exagen Inc. (XGN) - CERT

  • SEC Filings
  • 09/17/2019

Exagen Inc. (XGN) - CORRESP

  • SEC Filings
  • 09/16/2019

Exagen Inc. (XGN) - 8-A12B

  • SEC Filings
  • 09/13/2019

Exagen Inc. (XGN) - S-1/A

  • SEC Filings
  • 09/09/2019

Exagen Inc. (XGN) - CORRESP

  • SEC Filings
  • 08/26/2019

Exagen Inc. (XGN) - S-1

  • SEC Filings
  • 08/23/2019

Exagen Inc. (XGN) - DRSLTR

  • SEC Filings
  • 06/14/2019

Exagen Inc. (XGN) - DRS/A

  • SEC Filings
  • 06/14/2019

Exagen Inc. (XGN) - UPLOAD

  • SEC Filings
  • 02/27/2019

Exagen Inc. (XGN) - DRS

  • SEC Filings
  • 02/01/2019

Exagen Inc. (XGN) - D

  • SEC Filings
  • 02/01/2019

Exagen Inc. (XGN) - D

  • SEC Filings
  • 05/18/2017

Exagen Inc. (XGN) - D

  • SEC Filings
  • 04/10/2017

Exagen Inc. (XGN) - D

  • SEC Filings
  • 03/09/2017

Exagen Inc. (XGN) - D

  • SEC Filings
  • 02/01/2017

Exagen Inc. (XGN) - D

  • SEC Filings
  • 12/19/2016
Press Releases
StockPrice Release
More Headlines
News

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022

  • SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
  • 03/08/2022

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript

  • Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript
  • 11/13/2021

Exagen: Q3 Earnings Insights

  • Exagen (NASDAQ:XGN) reported its Q3 earnings results on Wednesday, November 10, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
  • 11/10/2021

Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

  • SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30th, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Monday, September 27th at 2:40 PM EDT.
  • 09/13/2021

Exagen Stock Gains As Q2 Financials Surpass Street Expectations

  • Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the consensus of $11.48 million. Its flagship AVISE CTD test, including AVISE Lupus, raked in $10.4 million in sales with the 94% Y/Y growth, indicating an acceleration from ~22% YoY recorded in Q1 2021.
  • 08/10/2021

XGN Stock Price Increases Over 34% Intraday: Why It Happened

  • The stock price of Exagen Inc. (Nasdaq: XGN) increased by over 34% during intraday trading. This is why it happened.
  • 08/10/2021

Exagen, Inc. (XGN) CEO Ron Rocca on Q2 2021 Results - Earnings Call Transcript

  • Exagen, Inc. (XGN) CEO Ron Rocca on Q2 2021 Results - Earnings Call Transcript
  • 08/10/2021

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

  • Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.00% and 9.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 08/09/2021

Exagen Inc. Reports Second Quarter 2021 Results

  • Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters
  • 08/09/2021

Exagen Appoints Ana Hooker to Board of Directors

  • SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional independent member to its Board of Directors, effective July 29, 2021.
  • 07/30/2021

Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference

  • SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference, which takes place August 10-12, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Thursday, August 12 at 12:00 PM EST.
  • 07/29/2021

AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions

  • SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupus & Science Medicine, found here: https://lupus.bmj.com/content/8/1/e000528.full. This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.
  • 07/13/2021

Exagen Elects Frank Stokes to Board of Directors

  • SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company's stockholders approved the election of Mr. Frank Stokes as an additional independent member to its Board of Directors at the Annual Meeting held on June 17, 2021. Mr. Stokes will also serve as Chair of the Audit Committee.
  • 06/18/2021

Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference

  • SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock Conference which takes place June 1-3, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, June 2 at 11:20 AM EDT.
  • 05/24/2021

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript

  • Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript
  • 05/11/2021

Exagen Inc. Reports First Quarter 2021 Results

  • Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters
  • 05/11/2021

Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

  • The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases
  • 05/04/2021

Exagen Announces New Campaign and Initiatives for Lupus Awareness Month

  • SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely diagnosis and patient monitoring for Systemic Lupus Erythematosus (SLE).
  • 05/03/2021

Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021

  • SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
  • 04/27/2021

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

  • SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus.
  • 03/29/2021

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

  • SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million.
  • 03/25/2021

Exagen Inc. Announces Pricing of Public Offering of Common Stock

  • SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares to be sold in the offering are to be sold by Exagen. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $60.1 million. In addition, Exagen has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock. The offering is expected to close on or about March 25, 2021, subject to the satisfaction of customary closing conditions.
  • 03/22/2021

Exagen Inc. Announces Proposed Public Offering of Common Stock

  • SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Exagen intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Exagen. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • 03/22/2021

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript

  • Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript
  • 03/16/2021

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

  • Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.18% and 16.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 03/16/2021

Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results

  • Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters
  • 03/16/2021

Exagen Inc. (XGN) Stock Jumps 6.8%: Will It Continue to Soar?

  • Exagen Inc. (XGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  • 03/03/2021

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021

  • SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
  • 03/02/2021

Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference

  • SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, March 3 at 4:00 pm EST.
  • 02/22/2021

Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  • SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, February 17 at 3:00 PM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.
  • 02/03/2021

Exagen Inc. Partners with Boston's Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

  • SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center.
  • 01/21/2021

Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results

  • Record Testing Revenue, Adopters and AVISE CTD® Volumes
  • 01/10/2021

Exagen Inc. To Participate in 2021 ICR Conference

  • SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes place January 11-14, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Thursday, January 14 at 11:30 AM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through the ICR Conference site.
  • 01/05/2021

Exagen Inc. Partners with Oregon's St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

  • SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System, the largest provider of medical care in Central Oregon.
  • 01/04/2021

Exagen (XGN) Looks Good: Stock Adds 9.3% in Session

  • Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
  • 01/04/2021

Exagen Inc. to Participate in December Investor Conferences

  • SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences:
  • 11/18/2020

Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management

  • SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world's leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.
  • 11/16/2020

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript

  • Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript
  • 11/10/2020

Exagen Inc. Reports Third Quarter 2020 Results

  • Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing
  • 11/10/2020

Exagen Inc. To Participate in November Investor Conferences

  • SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following November investor conferences.
  • 11/09/2020

Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection

  • SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a new study in collaboration with Brigham and Women's Hospital in Boston, MA. The Brigham is acknowledged internationally for its expertise and innovation in patient care, biomedical research, and educational training programs for physicians, scientists, and health care professionals.
  • 11/02/2020

Exagen to Announce Third Quarter Financial Results on November 10, 2020

  • SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 after the market close on Tuesday, November 10, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
  • 10/27/2020
Unlock
XGN Ratings Summary
XGN Quant Ranking